search
5/21/98

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 1998 ACS
AN 1997:23872 CAPLUS
DN 126:73609
TI Expressions of heat shock proteins under heat-stress and interferon-treatment: An in vitro study on osteosarcoma
AU Kubo, Toshikazu; Tamura, Yuji; Takahashi, Kenji; Imanishi, Jiro; Hirasawa, Yasusuke
CS Department Orthopaedic Surgery, Kyoto Prefectural University Medicine, Kamigyo, 602, Japan
SO Pathophysiology (1996), 3(4), 233-239
CODEN: PTHOE7; ISSN: 0928-4680
PB Elsevier
DT Journal
LA English
AB This study examd. expressions of heat shock proteins (HSP) under heat-stress and/or interferon (IFN)-.alpha., .beta., or .gamma. treatment using a human osteosarcoma cell line, NY cells. IFN alone as well as heat-stress at 43-45.degree. for 60 min suppressed cell growth, and their combination resulted in synergistic suppression. When primary heat stress was given, cells acquired thermotolerance at the second heat-stress. Autoradiog. revealed that HSP70 was mainly induced in the cells under heat-stress. In Western blot anal., heat (44.degree.)-induced HSP70 was suppressed by IFN treatment. This suggests that synergistic suppression effects of the combination treatment on osteosarcoma cells would be attributable to the suppression of HSP70 expressions. Optimum combination of heat-stress and IFN is expected to increase the cure rate in osteosarcoma treatment.
IT Interferon .alpha.
Interferon .beta.
Interferon .gamma.
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heat shock proteins expression under heat-stress and **interferon treatment** of **osteosarcoma**)

L7 ANSWER 2 OF 2 USPATFULL
AN 95:45355 USPATFULL
TI Controlled release of drugs or hormones in biodegradable polymer microspheres
IN Modi, Pankaj, 1298 Main St. W., Apt. 608, Hamilton, Ontario, Canada L8S 1J4
PI US 5417982 950523
AI US 94-197756 940217 (8)
DT Utility
EXNAM Primary Examiner: Griffin, Ronald W.
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 436
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A controlled release formulation for use with a variety of drugs or hormones are formed in microspherical form. The drug or hormone, e.g. bovine somatropine, is suspended in a polymer matrix. The polymer matrix is formed from at least two highly water soluble biodegradable polymers, selected for example from starch, crosslinked starch, ficoll, polysucrose, polyvinyl alcohol, gelatine, hydroxymethyl cellulose, hydroxyethyl